Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial.
Kohei ShitaraHiroki HaraTakaki YoshikawaKazumasa FujitaniTomohiro NishinaAyumu HosokawaTakashi AsakawaSatoe KawakamiKei MuroPublished in: International journal of clinical oncology (2019)
Results from this subgroup analysis of the JACOB trial suggest similar efficacy of pertuzumab in Japanese patients and patients in the overall population, encouraging continued investigation of new agents for gastric cancer in Japanese patients.
Keyphrases
- phase iii
- epidermal growth factor receptor
- end stage renal disease
- study protocol
- clinical trial
- metastatic breast cancer
- squamous cell carcinoma
- phase ii
- ejection fraction
- chronic kidney disease
- small cell lung cancer
- open label
- peritoneal dialysis
- randomized controlled trial
- papillary thyroid
- radiation therapy
- tyrosine kinase
- locally advanced
- squamous cell
- patient reported outcomes
- rectal cancer
- patient reported